- Home
- SENEB vs QURE Comparison
SENEB vs QURE Comparison
Compare SENEB & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SENEB
- QURE
- Stock Information
- Founded
- SENEB 1949
- QURE 1998
- Country
- SENEB United States
- QURE Netherlands
- Employees
- SENEB N/A
- QURE N/A
- Industry
- SENEB Packaged Foods
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- SENEB Consumer Staples
- QURE Health Care
- Exchange
- SENEB Nasdaq
- QURE Nasdaq
- Market Cap
- SENEB 703.0M
- QURE 725.4M
- IPO Year
- SENEB N/A
- QURE 2007
- Fundamental
- Price
- SENEB $101.56
- QURE $14.62
- Analyst Decision
- SENEB
- QURE Strong Buy
- Analyst Count
- SENEB 0
- QURE 10
- Target Price
- SENEB N/A
- QURE $37.20
- AVG Volume (30 Days)
- SENEB 580.0
- QURE 1.1M
- Earning Date
- SENEB 08-07-2025
- QURE 07-31-2025
- Dividend Yield
- SENEB N/A
- QURE N/A
- EPS Growth
- SENEB N/A
- QURE N/A
- EPS
- SENEB 5.90
- QURE N/A
- Revenue
- SENEB $1,578,887,000.00
- QURE $20,201,000.00
- Revenue This Year
- SENEB N/A
- QURE N/A
- Revenue Next Year
- SENEB N/A
- QURE $278.91
- P/E Ratio
- SENEB $16.97
- QURE N/A
- Revenue Growth
- SENEB 8.25
- QURE 6.30
- 52 Week Low
- SENEB $57.51
- QURE $4.45
- 52 Week High
- SENEB $107.99
- QURE $19.18
- Technical
- Relative Strength Index (RSI)
- SENEB 61.21
- QURE 50.64
- Support Level
- SENEB $101.00
- QURE $14.03
- Resistance Level
- SENEB $94.02
- QURE $15.16
- Average True Range (ATR)
- SENEB 0.45
- QURE 0.63
- MACD
- SENEB 0.22
- QURE 0.02
- Stochastic Oscillator
- SENEB 58.86
- QURE 67.88
About SENEB Seneca Foods Corp. Class B
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.